Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

• Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.
• Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating the pre-clinical process.
• 5.5 million women per year have HPV 16/18; of these 200,000 women per year are diagnosed with high grade dysplasia.

WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, recently announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (Nasdaq: MSFT), the world’s leading AI company.

Using Microsoft’s suite of advanced tools, Tevogen Bio is proactively investigating potential treatments for HPV to create a portfolio of oncology products. The company has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T cell (CTL) targets to choose for a clinical trial for TVGN 920, its first oncology product. Through Tevogen’s proprietary ExacTcell™ technology, where CTLs are trained to detect specific targets and then expanded, the company aims to be prepared to deliver an HPV-specific CTL treatment.

“Our ExacTcell technology, which has proven effective in developing SARS-CoV-2-specific CTLs, can be rapidly adapted to create CTL products targeting a wide range of viruses, including HPV,” said Dr. Neal Flomenberg, Chief Scientific Officer at Tevogen Bio. “While the specific targets may vary between viruses, the platform itself is well-established, enabling a swift response to emerging infectious threats.”

“By leveraging Microsoft’s cutting-edge AI and cloud technologies, we’re able to accelerate our target identification and pre-clinical processes in ways that weren’t previously possible,” said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. “Our partnership is allowing us to automate critical steps in the development pipeline, enhancing our readiness to quickly address additional indications, such as HPV.”

"With national healthcare cost and patient affordability at the forefront of our presidential candidates’ agendas, the urgency is clear,” commented Ryan Saadi, Founder and CEO, Tevogen Bio. “In 2023, U.S. healthcare spending reached an astounding $4.8 trillion - 17.6% of GDP - highlighting the potential impact on economic prosperity. As the new administration charts its course, Tevogen looks forward to being part of a sustainable solution."

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and numerous pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of experienced industry leaders and scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen related to the Business Combination; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701